

First author	Country (year)	Age (years) Experience group/Control group	Study population	Sample Size Experience/ Control group
(A)				
Shinji Ishikawa[20]	(Japan) 2014	73.7±7.3/69.0±8.0	T2DM and Cardiovascular diseases	37/39
Tomoya Mita[19]	(Japan) 2016b	64.4±9.8/64.8±9.1	T2DM	151/153
Tomoya Mita[21]	(Japan) 2016a	63.8±9.7/63.6±1.0	T2DM	121/122
Jun-ichi Oyama[22]	(Japan) 2016	69.2±9.3/69.5±9.2	T2DM	192/193
Murakami T.[23]	(Japan) 2018	NR	T2DM and Cardiovascular diseases	33/17
Murakami T.[24]	(Japan) 2015	NR	T2DM and Cardiovascular diseases	16/16
(B)				
Dimitrios Baltzis[25]	United States (2016)	60.79±5.75/56.76±6.79	T2DM	19/21
Gyuri Kim[26]	Korea (2017)	55.6±8.4/ 56.3±5.7	T2DM	17/17
Fang Li[27]	China (2017)	53.9±10.5/54.3±12.2	T2DM	14/13
murakami.T[28]	Japan (2013)	NR	T2DM and Cardiovascular diseases	17/17
murakami.T[23]	Japan (2018)	NR	T2DM and Cardiovascular diseases	33/17
Kazufumi Nakamura[16]	Japan (2014)	66.6±11.9/68.4±9.2	T2DM	24/31
Hiroshi Nomoto[29]	Japan (2016)	62±11.25/64±6	T2DM	41/49
Norbert J. Tripolt[30]	Austria (2018)	63.3±8.2/63.3±8.2	T2DM and Cardiovascular diseases	20/23
Tatsuya Maruhashi[31]	Japan (2016)	69.1±6.5/64.1±10.3	T2DM	17/18
Shigiyama[32]	Japan (2016)	60.4±9.0/60.02±4.4	T2DM	29/55
Kitao[33]	Japan (2017)	62(31to74)/60(20to74)	T2DM	46/43
Widlansky[34]	United States (2017)	63±9/62±10	T2DM	14/16
Suzuki 2012[35]	Japan (2012)	64.9±9.7/69.5±6.8	T2DM	12/12

(C)

Cosenso Martin[36]	Brazil (2018)	60.5±7.0/59.4±8.2	T2DM and Cardiovascular diseases	24/24
de Boer[41]	Netherlands (2017)	63±3.5/62±3.25	T2DM	21/19
Scalzo[37]	United States (2019)	59±2/60.08±4.23	T2DM	13/25
Awal[10]	United States (2020)	61±5/63±6	T2DM and CKD stages 1-3	14/17
Tomiyama 2016[38]	Japan (2016)	70±8/69±9	T2DM	45/51
Efstathiou, S. 2018[40]	Greece (2018)	NR	T2DM	32/34
Efstathiou, S. 2015[39]	Greece (2015)	NR	T2DM	52/54
Nedogoda 2020[42]	Russia (2020)	60.79±5.75/56.76±6.86	T2DM and Cardiovascular diseases	61/59
Zografou[43]	Greece (2015)	52±11.2/56±10.5	T2DM	32/32
